Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium
Main finding · Cost-effectivenessResult — go to the resultICER €19,978 per QALYAuthors' conclusion
Sequential treatment with romosozumab followed by alendronate was found to be cost-effective compared to alendronate monotherapy and dominant compared to teriparatide followed by alendronate for postmenopausal women with osteoporosis at high risk of fracture in Belgium.
Study context
- Population
- Postmenopausal osteoporotic women at high risk of fracture, Belgium
- Comparison
- Romosozumab followed by alendronate vs alendronate monotherapy and vs teriparatide followed by alendronate
- Outcome
- Costs per QALY (€ 2022)
- Follow-up
- Lifetime horizon
Methodological detailsMarkov microsimulation model, lifetime horizon, Belgian healthcare perspective (NIHDI), deterministic and probabilistic sensitivity analyses, Fracture risk reduction from the ARCH study and a published network meta-analysis, Belgium-specific epidemiological and cost data, where available
- Markov microsimulation model
- Lifetime horizon
- Belgian healthcare perspective (NIHDI)
- Deterministic and probabilistic sensitivity analyses
- Fracture risk reduction from the ARCH study and a published network meta-analysis
- Belgium-specific epidemiological and cost data, where available
Main finding
Cost-effectiveness
ICER
€19,978 per QALY
As reported in the abstract
Further findings
Sensitivity analyses
- Base-case results robust to uncertainty in the input parameters
Original publication
Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium. Osteoporos Int. Published 2 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →